CD8A and systemic lupus erythematosus: Baricitinib (100 nM) was effective in SLE CD4+ and SLE CD11b+ cells, while 300 nM baricitinib decreased the proportion of pSTAT3-expressing cells in all conditions significantly except for CD8+ SLE-derived T cells.